Search

Displaying results 2781 - 2790 of 10000 in total
  1. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101]. … It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates).

    Products: Human Albumin 20% Behring (Low Salt) Solution For Infusion
  2. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. … [L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal

  3. Drug

    Didanosine

    go.drugbank.com/drugs/DB00900
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative

  4. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.[L43942]

    Synonyms: N(1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
  5. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  6. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    [A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.

  7. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  8. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).

  9. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.

  10. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold